Non-invasive ventilation used as an adjunct to airway clearance treatments improves lung function during an acute exacerbation of cystic fibrosis: a randomised trial  by Dwyer, Tiffany J et al.
Journal of Physiotherapy 61 (2015) 142–147
J o u rn a l o f
PHYSIOTHERAPY
journal homepage: www.e lsev ier .com/ locate / jphysResearch
Non-invasive ventilation used as an adjunct to airway clearance treatments
improves lung function during an acute exacerbation of cystic ﬁbrosis:
a randomised trial
Tiffany J Dwyer a,b, Lisel Robbins c, Patrick Kelly d, Amanda J Piper a,e, Scott C Bell c,f, Peter T P Bye a,b
aDepartment of Respiratory and SleepMedicine, Royal Prince Alfred Hospital; b SydneyMedical School [3_TD$DIFF], University of Sydney; cAdult Cystic Fibrosis Centre, The Prince Charles Hospital;
d Sydney School of Public Health, University of Sydney; eWoolcock Institute of Medical Research, Sydney; fQIMR Berghofer Medical Research Institute, Brisbane, AustraliaK E Y W O R D S
Cystic ﬁbrosis
Non-invasive ventilation
Respiratory therapy
Physical Therapy
A B S T R A C T
Question: During an acute exacerbation of cystic ﬁbrosis, is non-invasive ventilation beneﬁcial as an
adjunct to the airway clearance regimen? Design: Randomised controlled trial with concealed allocation
and intention-to-treat analysis. Participants: Forty adults with moderate to severe cystic ﬁbrosis lung
disease and who were admitted to hospital for an acute exacerbation. Intervention: Comprehensive
inpatient care (control group) compared to the same care with the addition of non-invasive ventilation
during airway clearance treatments from Day 2 of admission until discharge (experimental group).
Outcome measures: Lung function and subjective symptom severity were measured daily. Fatigue was
measured at admission and discharge on the Schwartz Fatigue Scale from 7 (no fatigue) to 63 (worst
fatigue) points. Quality of life and exercise capacity were also measured at admission and discharge.
Length of admission and time to next hospital admissionwere recorded.Results:Analysed as the primary
outcome, the experimental group had a greater rate of improvement in forced expiratory volume in
1 second (FEV1) than the control group, but this was not statistically signiﬁcant (MD 0.13% predicted per
day, 95% CI –0.03 to 0.28). However, the experimental group had a signiﬁcantly higher FEV1 at discharge
than the control group (MD 4.2% predicted, 95% CI 0.1 to 8.3). The experimental group reported
signiﬁcantly lower levels of fatigue on the Schwartz fatigue scale at discharge than the control group (MD
6 points, 95% CI 1 to 11). There was no signiﬁcant difference between the experimental and control
groups in subjective symptom severity, quality of life, exercise capacity, length of hospital admission or
time to next hospital admission. Conclusion: Among people hospitalised for an acute exacerbation of
cystic ﬁbrosis, the use of non-invasive ventilation as an adjunct to the airway clearance regimen
signiﬁcantly improves FEV1 and fatigue. Trial registration: ANZCTR 12605000437662. [Dwyer TJ,
Robbins L, Kelly P, Piper AJ, Bell SC, Bye PTP (2015) Non-invasive ventilation used as an adjunct to
airway clearance treatments improves lung function during an acute exacerbation of cystic ﬁbrosis:
a randomised trial. Journal of Physiotherapy 61: 142–147]
 2015 Published by Elsevier B.V. on behalf of Australian Physiotherapy Association. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Airway clearance is an integral component of the respiratory
management of cystic ﬁbrosis (CF).1 During acute exacerbations of
their lung disease, people with CF often ﬁnd it difﬁcult to maintain
effective airway clearance due to increased breathlessness,
lethargy and respiratory muscle fatigue.2 Studies have shown
that the addition of non-invasive ventilation (NIV) to a single
treatment of physiotherapy techniques for airway clearance assists
in overcoming these issues.3 However, it is not knownwhether NIV
is a beneﬁcial adjunct to physiotherapy treatments for airway
clearance if used throughout a hospital admission for an acute
exacerbation of CF.
The efﬁcacy of NIV as an airway clearance technique in CF has
been examined in several single-session crossover trials. Mucus
clearance, as measured by inhaled radioaerosol4 and expectoratedhttp://dx.doi.org/10.1016/j.jphys.2015.05.019
1836-9553/ 2015 Published by Elsevier B.V. on behalf of Australian Physiotherapy A
creativecommons.org/licenses/by-nc-nd/4.0/).sputum volume,5–7 was not different with the application of NIV
when compared to resting breathing alone4 or standard chest
physiotherapy.5–7 In addition, there were no differences in lung
function, as measured by spirometry, following standard chest
physiotherapy and NIV-assisted treatment.5–8
However, this does not preclude a role for NIV as an adjunct to
airway clearance physiotherapy for people with CF. In several
studies, participants reported greater ease of expectoration,5 less
breathlessness6 and less fatigue5,7 when standard chest physio-
therapy treatment was assisted with NIV. Additionally, partici-
pants reported that they preferred treatment with NIV compared
to standard chest physiotherapy.5,6,8 The improvements in
breathlessness, fatigue and ease of expectoration may be at least
partly explained by the preservation of respiratorymuscle strength
with NIV-assisted treatment compared to standard chest physio-
therapy.5,6 This effect on respiratory muscle strength suggests thatssociation. This is an open access article under the CC BY-NC-ND license (http://
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manoeuvres with less effort or tolerate more effective airway
clearance techniques with the support of NIV, especially when
most required – during an acute exacerbation.
Despite the promising results of single-session applications of
NIV during airway clearance treatment in people with CF, to date,
no study has examined the efﬁcacy of NIV over a longer period of
time.3 Therefore, the research questions for this study were:1. In adults with moderate to severe CF lung disease and who are
admitted to hospital with an acute exacerbation, does the
addition of NIV to chest physiotherapy improve the rate of
change and discharge values of lung function and subjective
symptom severity?2. Does it improve the change in respiratory muscle strength
following chest physiotherapy?3. Does it improve quality of life, fatigue score, exercise capacity
and quantitative sputum microbiology at discharge?4. Does it reduce the length of hospital admission and lengthen the
time to next hospital admission for an acute exacerbation of CF?
Methods
Design
A parallel-group, randomised controlled trial was conducted in
two tertiary Australian hospitals with specialist CF units. After
signing consent to participate, patients were assigned to the control
group (standard comprehensive inpatient care from the CF team) or
the experimental group (standard care plus NIV during chest
physiotherapy). Group allocation was determined by computer-
generated block randomisation, which was stratiﬁed for hospital
and gender. Randomisationwas performedby a personnot involved
in the study and stored in sealed, sequentially numbered, opaque
envelopes, which were opened after the participant had signed
consent. The participants, treating therapists and independent
assessors were not blinded to treatment group allocation. Partici-
pants in the experimental group used NIV during chest physiother-
apy from Day 2 of admission until discharge from hospital.
Spirometry and subjective symptom severity were recorded daily
throughout the admission. All other outcome measures were
collected on admission to and discharge from hospital.
Participants, therapists and centres
All patients who were aged over 17 years and admitted with an
acute exacerbation of CF to the Royal Prince Alfred Hospital,
Sydney, and Prince Charles Hospital, Brisbane, were assessed for
inclusion in the study. An acute exacerbation of CF was deﬁned as
the need for intravenous antibiotics with the presence of four or
more signs or symptoms, according to the criteria used by Fuchs
et al.9 Patients with moderate to severe CF lung disease were
included in the study if their forced expiratory volume in 1 second
(FEV1) on admission < 60% of the predicted value.
10 Patients were
excluded from the study if[2_TD$DIFF] they[5_TD$DIFF]: were using domiciliary NIV for the
treatment of respiratory failure, hadprecautions to theuse ofNIV (eg,
pneumothorax, recent severe haemoptysis), were colonised with
Burkholderia cepacia complex, were pregnant or had already
participated in the study. The physiotherapy staff rostered to the
respiratory inpatientwardsapplied the interventionsafterdiscussion
with a senior physiotherapist not otherwise involved in the study.
Interventions
A senior respiratory physiotherapist, who was not otherwise
involved in the study, individually assessed all participants and
determined the type, frequency and duration of chest physiother-
apy treatmentwith the participant. During chest physiotherapy, allparticipants performed the active cycle of breathing technique,
which consists of cycles of deep breathing, relaxed breathing,
hufﬁng and coughing in order to aid mucus clearance.11 In
addition, the physiotherapist determined whether to incorporate
any additional techniques, includingmanual percussion, vibration,
postural drainage positioning, autogenic drainage, positive expi-
ratory pressure (PEP) and oscillating PEP.
Non-invasive ventilation treatment
Participants assigned to the experimental group underwent an
acclimatisation session on the day of admission. During this time,
the appropriate inspiratory and expiratory pressures were deter-
mined, and an interface (nasal mask or mouthpiece) was chosen
that maximised participant comfort and efﬁcacy (pressure
support), whilst minimising leak. On Day 2 of admission,
participants assigned to the experimental group were provided
with a NIV machinea with inbuilt humidiﬁerb and were instructed
to use NIV during all chest physiotherapy sessions for the rest of
their hospital admission. NIV use was recorded with the inbuilt
storage cardc and downloaded at discharge from hospital.
Outcome measures
Spirometry, which was the primary outcome measure, was
performed daily to determine the rate of change in FEV1. Subjective
symptom severity was also recorded daily for breathlessness,
expectorated sputum volume and energy levels on 10-cm visual
analogue scales (breathlessness: 0 = nothing at all, 10 = the
maximal I have ever experienced; expectorated sputum volume:
0 = none at all, 10 = as much as I have ever had; energy: 0 = full of
beans, 10 = no energy at all). Maximal inspiratory (PImax) and
expiratory (PEmax) pressure12 weremeasured immediately before
and after chest physiotherapy on Day 2 of admission, 1 week after
admission and at discharge from hospital. At admission and
discharge fromhospital, participants also completed the CFQ (a CF-
speciﬁc quality of life questionnaire),13 the Schwartz fatigue
scale,14 and the 25-level modiﬁed shuttle test to assess exercise
capacity.15 Sputum samples were collected at admission (prior to
commencement of intravenous antibiotics), 1 week after admis-
sion and at discharge from hospital. Samples were couriered on ice
to a central laboratory for quantitative microbiological analysis,
which was performed by a blinded assessor. Organisms were
identiﬁed with the use of standard microbiological techniques,
including the API 20 NE systemd and quantiﬁcation of pathogens
was performed with the use of the modiﬁcations of Wong and
colleagues.16 The length of admission and time to next hospital
admission for an acute exacerbation9 of CF were recorded.
Data analysis
The primary outcome measure was rate of change in FEV1 (% of
predicted per day) from admission to discharge from hospital. Data
from10 patients of similar lung function severity (ﬁve from each of
the hospitals in this study) showed a standard deviation of 0.49% of
predicted per day. With an anticipated effect size of 0.5,
17 participants in each group would give 80% power to detect a
signiﬁcant difference (a < 0.05) between the two groups. To allow
for a 15% dropout rate, we sought to recruit 40 people to the study.
Repeated-measures analyses were performed using linear
mixed models to determine if the [6_TD$DIFF]rates of improvement in FEV1
and symptom severity were different between the experimental
and control groups. The models included ﬁxed effects for group
(experimental or control), time (day of admission), and the group
by time interaction. A random effect for the intercept (ie, the
participant) was included. Independent-samples t-tests, adjusting
for the participants’ admission values, were performed to compare
the discharge values between the experimental and control groups
for FEV1, symptom severity, quality of life, exercise capacity and
quantitative sputum microbiology. Independent-samples t-tests
were calculated to determine whether there were differences
[(Figure_1)TD$FIG]
Figure 1. Design and ﬂow of participants through the trial.
B. cepacia = Burkholderia cepacia, CF = cystic ﬁbrosis, FEV1 = forced expiratory volume in 1 second, NIV = non-invasive ventilation.
a One participant in the experimental group did not tolerate NIV andwithdrew from further intervention and data collection fromDay 2, so was not able to be included in the
analyses of rate of improvement or discharge, but was included in the calculation of length of stay and time to readmission.
b On Day 1, one participant in the control group withdrewwithout providing a reason, so was not able to be included in the analyses of rate of improvement or discharge, but
was able to be included in the calculation of length of stay and time to readmission.
c One participant in the experimental group received a lung transplant at Day 19 of the admission, so was able to be included in the rate of improvement analysis but was not
able to be included in the discharge analysis or the calculation of length of stay and time to readmission.
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respiratorymuscle strength following chest physiotherapy and the
length of admission. Cox proportional-hazards regression was
calculated to compare the time to next hospital admission in the
experimental and control groups. Data were analysed on an
intention-to-treat basis and statistical signiﬁcance was set at
p = 0.05 for all calculations.
Results
Flow of participants, therapists and centres through the trial
Over a 26-month period, 40 participants consented to the study
protocol and underwent randomisation (Figure 1). Three partici-
pants withdrew from the study and the data from these
participants were used, as available and appropriate, in theanalyses of daily rate of improvement[7_TD$DIFF], length of stay and time to
next hospital admission. The experimental and control groups
were similar at baseline (Table 1 and ﬁrst two columns of Table 2).
Compliance with study protocol
All participants performed the active cycle of breathing
technique. In addition, physiotherapists applied techniques of
manual percussion, vibration and postural drainage positioning,
autogenic drainage, PEP and oscillating PEP (Table 3). One of the
19 participants in the experimental group did not tolerate NIV and
withdrew from the study. The average inspiratory pressure was
13 cmH2O (SD 2, range 10 to 19), average expiratory pressure was
5 cmH2O (SD 1, range 4 to 7) and average pressure support
(difference between inspiratory and expiratory pressure) was
8 cmH2O (SD 3, range 6 to 15). The average daily NIV use was
65 minutes (SD 31, range 26 to 135).
[(Figure_2)TD$FIG]
Figure 2. Daily rate of improvement in FEV1 (% predicted)
10 from admission until
Day 14, and discharge for the experimental group (closed circles) and the control
group (open circles).
*p = 0.04.
Table 1
Characteristics of participants at admission to hospital.
Characteristic Exp Con
(n=19) (n=21)
Age (yr), mean (SD) 28 (7) 30 (9)
Gender, n female (%) 6 (32) 8 (38)
BMI (kg/m2), mean (SD) 21.4 (3.1) 20.4 (3.0)
FVC (% predicted), mean (SD) 61 (15) 63 (15)
PImax (% predicted), mean (SD) 87 (32) 93 (30)
PEmax (% predicted), mean (SD) 70 (22) 92 (41)
BMI = bodymass index, Con = control group, Exp = experimental group, FVC = forced
vital capacity, PEmax = maximal expiratory pressure, PImax = maximal inspiratory
capacity.10,12
Table 3
Physiotherapy techniques applied during the admission.
Technique, n (%) Exp Con
(n=18) (n=20)
Manual techniques 18 (100) 20 (100)
PEP 6 (33) 16 (80)
Oscillating PEP 1 (6) 1 (5)
Autogenic Drainage 0 (0) 3 (15)
All participants performed the active cycle of breathing technique. In addition,
physiotherapists applied manual techniques of percussion, vibration and postural
drainage positioning to all participants. Two participants in the control group
performed PEP and autogenic drainage. One participant in the experimental group
performed independent oscillating PEP without NIV for some physiotherapy
treatments. One participant in the experimental group performed independent PEP
without NIV for some physiotherapy treatments. Five participants in the
experimental group performed PEP with NIV.
PEP = positive expiratory pressure.
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intravenous antibiotics commenced or no courier was available to
transport samples to the centralised laboratory. Therefore, sputum
samples were analysed for only 14/19 participants in the
experimental group and 18/21 participants in the control group
at admission and discharge.
Effect of the intervention
Most of the study outcomes are presented in Table 2, with
individual participant data presented in Table 4 (see eAddenda for
Table 4).
Lung function
There was a non-signiﬁcant trend for the experimental group to
have a greater daily rate of improvement in FEV1 (% predicted) than
the control group,with amean difference of 0.13% per day (95% CI –
0.03 to 0.28), as shown in Figure 2. At discharge, the experimental
group had a signiﬁcantly higher FEV1 (% predicted) than the control
group (Table 2).
Subjective symptom severity and quality of life
There was no signiﬁcant difference in the daily rate of
improvement between the experimental and control groups for
any domain (breathlessness MD 0.05 cm/day, 95% CI –0.07 to 0.18;
expectorated sputum volume MD 0.00 cm/day, 95% CI –0.06 to
0.06; energy MD –0.07 cm/day, 95% CI –0.20 to 0.06). At discharge,
there was also no difference between the experimental and control
groups in the participants’ rating of breathlessness, expectorated
sputum volume and energy levels (Table 2).
At discharge, there was no signiﬁcant difference between the
experimental and control groups in the physical, health and
respiratory domains of the CFQ (Table 2). The experimental group[1_TD$DIFF] able 2
Mean (SD) of each group at admission and at discharge from hospital, and mean (95%
Outcome Gr
Admission
Exp (n=19) Con (n=21)
FEV1 (% predicted) 36.1 (10.4) 39.1 (10.2)
MST-25 distance (m) 737 (349) 776 (413)
P. aeruginosa density (log CFU/g) a 7.44 (2.23) 7.57 (0.78)
CFQ – physical 36 (19) 37 (24)
CFQ – health 43 (23) 32 (19)
CFQ – respiratory 42 (16) 37 (15)
Fatigue 43 (12) 44 (12)
Breathlessness – VAS (cm) 5.6 (2.2) 6.0 (2.4)
Sputum volume – VAS (cm) 5.1 (2.1) 6.4 (1.8)
Energy – VAS (cm) 6.4 (2.0) 5.7 (1.9)
Comparisons between the experimental and control groups are shown as estimated grou
the Schwartz fatigue scale (minimum score =7, maximum score=63, lower values repr
CFQ = CF-quality of life questionnaire, with physical, health and respiratory domains (min
Con = control group, Exp = experimental group, FEV1 = forced expiratory volume in 1 seco
test, P. aeruginosa = Pseudomonas aeruginosa, calculated as the percentage of participants
per gram of sputum, expressed as log values on a base 10 scale (log CFU/g), VAS=10-c
a Sputum samples were analysed for 14/19 participants in the experimental group areported signiﬁcantly less fatigue at discharge than the control
group using the Schwartz fatigue scale (Table 2).
Respiratory muscle strength following chest physiotherapy
On Day 2 of the admission, the PImax and PEmax worsened
following standard chest physiotherapy (control group) andCI) difference between groups at discharge.
oups Difference between groups
Discharge Discharge
Exp (n=17) Con (n=20) Exp minus Con
49.5 (14.3) 48.2 (12.1) 4.2 (0.1 to 8.3)
914 (343) 929 (418) –13 (–86 to 61)
6.77 (1.68) 7.71 (0.88) –0.86 (–1.79 to 0.06)
54 (27) 58 (22) –3 (–14 to 8)
59 (24) 56 (24) –5 (–19 to 8)
62 (17) 51 (15) 8 (–2 to 18)
37 (13) 43 (8) –6 (–11 to –1)
1.9 (1.3) 2.1 (2.0) –0.2 (–1.3 to 1.0)
2.0 (1.4) 2.5 (2.2) –0.4 (–1.7 to 0.9)
3.2 (1.7) 3.2 (2.1) –0.1 (–1.5 to 1.2)
pmean differences, adjusted for admission values, with 95% CI. Fatiguemeasured on
esent less fatigue).
imum score =0,maximum score =100, higher values represent better quality of life),
nd as percent of predicted normal lung volume, MST-25=25-level modiﬁed shuttle
in each group colonised in sputum and density of P. aeruginosa colony forming units
m visual analogue scale (higher values represent feeling more symptomatic).
nd 18/21 participants in the control group at admission and discharge.
[(Figure_3)TD$FIG]
Figure 3. Change in respiratory muscle strength following chest physiotherapy on
Day 2 of admission. On the left is the change in maximal inspiratory pressure
(PImax) from immediately before to immediately after chest physiotherapy for the
experimental group (black column) and the control group (white column). On the
right is the change in maximal expiratory pressure (PEmax) from immediately
before to immediately after chest physiotherapy for the experimental group (black
column) and the control group (white column).
PEmax = maximal expiratory pressure, PImax = maximal inspiratory pressure.
*p = 0.006.
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mental group). Themean difference in PImaxwas 8 cmH2O (95% CI
2 to 14) and themean difference in PEmaxwas 6 cmH2O (95% CI –3
to 15), as shown in Figure 3. When PImax and PEmax were re-
measured before and after chest physiotherapy 1 week into the
admission and on discharge from hospital, there was no difference
in the change in respiratory muscle strength between the
experimental and control groups.
Exercise capacity
At discharge, there was no signiﬁcant difference in distance
covered in the 25-level modiﬁed shuttle test between the two
groups (Table 2).
Quantitative sputum microbiology
Pseudomonas aeruginosa was identiﬁed in all sputum samples,
except in one sample from a participant in the experimental group
at admission. On quantitative microbiology, the experimental
group had a signiﬁcantly lower Pseudomonas aeruginosa colony
count than the control group at 1 week after admission (mean
difference –1.12 log CFU/g, 95% CI –0.04 to –2.20). At discharge,
there was also a non-signiﬁcant trend for the experimental group
to have a lower Pseudomonas aeruginosa colony count than the
control group (Table 2).
[(Figure_4)TD$FIG]Figure 4. Time to next hospital admission for an acute exacerbation of CF for the
control group (dotted line) and experimental group (solid line).Length of hospital admission and time to next hospital admission
There was no signiﬁcant difference between the experimental
and control groups in the length of hospital admission. The mean
length of stay was 14.7 days (SD 3.9) in the [8_TD$DIFF]control group and
14.2 days (SD 4.0) in the [9_TD$DIFF]experimental group (MD –0.4 days, 95% CI
–3.0 to 2.1). There was no signiﬁcant difference between the
experimental and control groups for the time to next hospital
admission for an acute exacerbation of CF, as deﬁned by the criteria
of Fuchs et al,9 with a hazard ratio for re-admission in the
experimental group of 0.78, p = 0.44 (Figure 4).
Adverse events
There were no adverse events in either group.
Discussion
Non-invasive ventilation-assisted chest physiotherapy applied
during a hospital admission for an acute exacerbation of CF
resulted in signiﬁcantly higher FEV1 (% predicted) at discharge than
standard chest physiotherapy alone. However, the group who
received NIV-assistance to the chest physiotherapy only showed a
non-signiﬁcant trend towards a greater daily rate of improvement
in FEV1 (% predicted), whichwas the primary outcome of the study.
At discharge, the improvement in lung function may have been
related to the reduced sputum bacterial load and the preservation
of respiratory muscle strength with chest physiotherapy for those
using NIV during the early stages of the hospital admission.
Participants in the experimental group reported signiﬁcantly
lower levels of fatigue on discharge from hospital compared to the
control group. This reduction in fatigue was also reported in other
trials of people with CF when NIV-assistance was added to a single
session of chest physiotherapy.5,7 Potentially, the lower levels of
fatigue are related to the preservation of respiratory muscle
strength following NIV-assisted chest physiotherapy, which has
been demonstrated in previous studies5,6 as well as this study.
Interestingly, the improvement in respiratory muscle strength
following NIV-assisted chest physiotherapy in this study was only
evident when measured on Day 2 of admission. When respiratory
muscle strength was measured before and after chest physiother-
apy 1 week into the admission and at discharge from hospital,
there was no difference between the experimental and control
groups. Perhaps the unloading of the respiratory muscles with NIV
is most effective when people with CF are the most unwell and
they have a higher work of breathing.
Despite having greater improvements in lung function and
fatigue, the experimental group reported similar improvements in
symptom severity to the control group, both in the rate of
improvement and discharge values. Perhaps the improvements in
symptoms and quality of life from admission to discharge from
hospital are so great that subjective scoring is unable to detect the
differences between types of chest physiotherapy.
Surprisingly, considering the improvements in lung function
and fatigue, the participants in the experimental group had no
greater improvement in exercise capacity at discharge than those
in the control group. Both groups had marked improvements in
exercise capacity, from admission to discharge, with average
improvements of 150 m on the 25-level modiﬁed shuttle test,
where an improvement of 40 m is considered to be clinically
signiﬁcant.17
High sputum bacterial load is a major cause of morbidity in CF.
In this study, the experimental group had greater reductions in the
sputum Pseudomonas aeruginosa density than the control group,
both at 1week into the admission and at discharge fromhospital. It
is possible that NIV-assistance augmented the mucus clearance
with chest physiotherapy, to help lower the sputum bacterial load,
which in turn may have contributed to the greater improvements
in lung function for the experimental group.
Lung function is often the major determinant for a physician to
decide when a patient should be admitted to hospital and when
Research 147they are well enough to go home. In this study, although
participants in the experimental group had slightly faster rates
of improvement in lung function, there was no difference in length
of hospital stay between the two groups. In addition, despite
leaving hospital with signiﬁcantly higher FEV1, there was no
difference in the time to next hospital re-admission for an acute
exacerbation between the two groups.
Although not formally measured in this study, the addition of
NIV to chest physiotherapy was well tolerated, which was similar
to previous single-session trials of NIV.4–8 The average daily NIV
use was 65 minutes. Only one of 19 participants in the
experimental group refused NIV treatment due to poor tolerance,
and therewere no adverse events associatedwithNIV. The range in
pressure support applied with NIV in this study (6 to 15 cmH2O)
was similar to that of previous trials;4–7 however, the average
pressure support was only 8 cmH2O, which may have been
insufﬁcient to adequately support inspiratory effort and unload the
respiratory muscles for those receiving lower inspiratory pressure.
Perhaps higher levels of inspiratory pressure could have been
tolerated as participants became more accustomed to the
treatment later in the admission, possibly allowing NIV treatment
to have beenmore effective, rather thanmaintaining the same NIV
settings as determined in the acclimatisation session on the day of
admission.
This investigation into the efﬁcacy of NIV as an adjunct to chest
physiotherapy during an exacerbation of CF lung disease is a
difﬁcult setting in which to identify between-group differences.
This is because the standard care received by both groups
(intravenous antibiotics and comprehensive input from the CF
team) is so effective, as reﬂected in the marked improvements in
exercise tolerance and lung function for both groups in this study.
Perhaps if the study had targeted more severe CF patients or those
with signiﬁcantly increased work of breathing and intolerance to
standard chest physiotherapy, more differences would have been
found between the treatment groups. Another limitation of this
study was that participants, clinicians and independent assessors
were not blinded to treatment allocation. Complete blinding of
treatment allocation would have been impossible; however,
introducing a third group with sham NIV or continuous positive
airway pressure (CPAP) may have provided some blinding to
participants and independent assessors.
In summary, the use of NIV as an adjunct to chest physiotherapy
during a hospital admission for an acute exacerbation of CF
signiﬁcantly improved lung function and fatigue on discharge from
hospital. This improvement in lung function, however, was not
matched by improvements in symptom severity, exercise capacity,
length of hospital stay, or the exacerbation-free period after
discharge from hospital. It is very difﬁcult to show improvements
over comprehensive inpatient care; however, the results of this
study suggest that the addition of NIV to standard chest
physiotherapy is a useful tool to aid airway clearance, especially
when people with moderate to severe CF lung disease are most at
risk of respiratory muscle fatigue. Future trials targeting people
with more-severely affected lungs or continuing the addition of
NIV to chest physiotherapy after discharge from hospital would
further evaluate the role of NIV in CF care.What is already known on this topic: People with cystic
fibrosis often find it hard tomaintain effective airway clearance
during acute exacerbations of their lung disease due to in-
creased breathlessness and respiratory muscle fatigue. When
used as an adjunct to a single session of airway clearance
techniques, non-invasive [10_TD$DIFF]ventilation reduces these symptoms
and improves ease of expectoration.
What this study adds: When non-invasive ventilation was
used as an adjunct to chest physiotherapy throughout a
hospital admission by adults with an acute exacerbation of
cystic fibrosis lung disease, they left hospital with better lung
function and less fatigue.Footnotes: a VPAP III, ResMed, Bella Vista, Australia; b H2i,
ResMed, Bella Vista, Australia; c ResLink, ResMed, Bella Vista,
Australia; d BioMerieux Vitek, Durham, USA
eAddenda: Table 4 can be found online at doi:10.1016/j.jphys.
2015.05.019.
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